Mr. Nick Karos reports

UNIVERSAL IBOGAINE ADVISES OF DEBT SETTLEMENT WITH CEO AND RESIGNATION OF A MEMBER OF ITS BOARD OF DIRECTORS

Ken Cranwill has resigned from the board of directors of Universal Ibogaine Inc. to focus on his other business ventures.

Nick Karos, chief executive officer and director, noted, "On behalf of the board of directors, the company thanks Ken for his service on the board over the past year."

Universal Ibogaine also advises that it has received approval from the TSX Venture Exchange to settle a portion, totalling $106,200, of arrears consulting fees owed to its Mr. Karos. As previously announced (see news release dated April 3, 2025), the company will issue 4,248,000 common shares (subject to applicable hold periods) at a price of 2.5 cents per share in settlement of this debt.

Following closing of this share issuance, Universal Ibogaine will have a total of 312,858,516 common shares outstanding.

About Universal Ibogaine Inc.

Universal Ibogaine is a life science company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder and, ultimately, to utilize that treatment protocol globally through planned future licensing agreements. Universal Ibogaine is concurrently developing a state-of-the-art holistic addiction treatment protocol at its Kelburn Recovery Centre (located near Winnipeg, Man.) that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way addiction is treated and drastically improve the lives of individuals and families affected by addiction.

We seek Safe Harbor.